ArticleCureus2026
Clinicopathological Features and Prognostic Impact of Human Epidermal Growth Factor Receptor 2-Low Status in Early-Stage Breast Cancer: A Single-Center Cohort Hormone Receptor-Stratified Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction This study evaluates the prevalence, clinicopathological features, and prognostic impact of human epidermal growth factor receptor 2-low (HER2-low) on breast cancer (BC), focusing on hormone receptor (HR)-stratified outcomes. Materials and methods We retrospectively analyzed 97 patients with HER2-negative invasive BC from 2017 to 2024 at a single center. Data were compared between HER2-low and HER2-0 cohorts, stratified by HR status. Survival outcomes, including disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS), were estimated using Kaplan-Meier methodology. Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic effect of HER2-low on DFS. Results The prevalence of HER2-low was 61.9%, with 83.3% of our cases being hormone receptor-positive (HR+). HER2-low/HR+ tumors showed significant disparities in clinical T-stage (p=0.029) compared to HER2-0/HR+ cases. In the hormone receptor-negative (HR-) subgroup, HER2-low tumors exhibited significantly higher lymphovascular invasion (p=0.035) and high cellular proliferation, with all cases having Ki-67 > 20%. In our cohort, lymph node ratio (LNR) risk category and Ki-67 index were identified as the primary independent predictors of DFS. While HER2-low status showed a trend toward increased hazard in univariate analysis, it did not maintain independent significance in the multivariable model (p=0.217). Notably, subgroup analysis demonstrated that the protective effect of HR positivity was significantly more robust within the HER2-low population (p=0.008) compared to the HER2-0 group (p=0.221). Conclusions HER2-low BC is highly prevalent in our cohort but does not independently influence early-stage prognosis. Instead, underlying tumor biology, specifically proliferation (Ki-67) and nodal burden (LNR), remains the primary driver of clinical outcomes. Hormone receptor positivity was associated with favorable survival within the HER2-low subgroup, although non-significant interaction testing underscores that these subgroup observations are exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.